GSK Bolsters Orphan Drug Discovery By Signing Antisense Deal With Isis
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the deal, which has all the hallmarks of a GSK option-based alliance, Isis gets $35 million upfront, and will deliver five drugs through PoC.